References

  1. Tamiflu®(oseltamivir phosphate) Prescribing Information. South San Francisco, CA: Genentech USA, Inc.; January, 2013.
  2. Centers for Disease Control and Prevention. Seasonal influenza. http://www.cdc.gov/flu/about/qa/disease.htm . Accessed August 21, 2013.
  3. Centers for Disease Control and Prevention. The influenza (flu) viruses. http://www.cdc.gov/flu/about/viruses/index.htm . Accessed August 21, 2013.
  4. Centers for Disease Control and Prevention. Flu symptoms & severity. http://www.cdc.gov/flu/about/disease/symptoms.htm . Accessed August 21, 2013.
  5. Centers for Disease Control and Prevention. People at high risk of developing flu-related complications. http://www.cdc.gov/flu/about/disease/high_risk.htm . Accessed August 21, 2013.
  6. Centers for Disease Control and Prevention. Updated CDC estimates of 2009 H1N1 influenza cases, hospitalizations and deaths in the United States, April 2009-April 10, 2010. http://www.cdc.gov/h1n1flu/estimates_2009_h1n1.htm . Accessed August 21, 2013.
  7. Centers for Disease Control and Prevention. Flu View. 2008-2009 influenza season week 12 ending March 28, 2009. http://www.cdc.gov/flu/weekly/weeklyarchives2008-2009/weekly12.htm . Accessed August 21, 2013.
  8. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001;20:127-133.
  9. Poehling KA, Edwards KM, Weinberg GA, et al; New Vaccine Surveillance Network. The underrecognized burden of influenza in young children. N Engl J Med. 2006;355:31-40.
  10. Centers for Disease Control and Prevention. Role of laboratory diagnosis of influenza. http://www.cdc.gov/flu/professionals/diagnosis/labrole.htm . Accessed August 21, 2013.
  11. Centers for Disease Control and Prevention. Interim results: influenza A (H1N1) 2009 monovalent vaccination coverage — United States, October - December 2009. MMWR Morb Mortal Wkly Rep. January 22, 2010; 59:44-48.
  12. Centers for Disease Control and Prevention. ACIP recommendations: introduction and biology of influenza. http://www.cdc.gov/flu/professionals/acip/background.htm . Accessed August 21, 2013.
  13. Centers for Disease Control and Prevention. Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009-2010 season. http://www.cdc.gov/h1n1flu/recommendations.htm . Accessed August 21, 2013.
  14. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA. 2000;283:1016-1024.
  15. Data on file, Genentech USA, Inc.
  16. Jain S, Kamimoto L, Bramley AM, et al; 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009;361:1935-1944.
  17. National Institute of Allergy and Infectious Diseases. Is it a cold or the flu? http://www.niaid.nih.gov/topics/Flu/Documents/sick.pdf . Accessed August 21, 2013.
  18. Atkinson W, Hamborsky J, McIntyre L, Wolfe S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 11th ed. Washington, DC: Public Health Foundation; 2009:135-154. http://www.cdc.gov/vaccines/pubs/pinkbook/default.htm . Accessed August 21, 2013.
  19. Centers for Disease Control and Prevention. Flu View. 2008-2009 influenza season week 35 ending September 5, 2009. http://www.cdc.gov/flu/weekly/weeklyarchives2008-2009/weekly35.htm . Accessed August 21, 2013.
  20. Centers for Disease Control and Prevention. Flu View. 2009-2010 influenza season week 20 ending May 22, 2010. http://www.cdc.gov/flu/weekly/weeklyarchives2009-2010/weekly20.htm . Accessed August 21, 2013.
  21. Centers for Disease Control and Prevention. Rapid diagnostic testing for influenza. Information for health care professionals. http://www.cdc.gov/flu/professionals/diagnosis/rapidclin.htm .
  22. Welliver R, Monto A, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001;285(6):748-754.
  23. Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis. 2004;189:440-449.
  24. Centers for Disease Control and Prevention. Vaccine selection for the 2011-2012 and 2012-2013 influenza seasons: questions & answers. http://www.cdc.gov/flu/about/qa/vaccine-selection.htm . Accessed August 21, 2013.
  25. Centers for Disease Control and Prevention. FluView 2012-2013 influenza season week 20 ending May 18, 2013. http://www.cdc.gov/flu/weekly/weeklyarchives2012-2013/weekly20.htm . Accessed September 21, 2013.
  26. Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza — United States, 1976-2007. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5933a1.htm . Accessed August 21, 2013.
  27. Centers for Disease Control and Prevention. Summary Recommendations: Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) - United States, 2013-14. http://www.cdc.gov/flu/professionals/acip/2013-summary-recommendations.htm . Accessed September 25, 2013.
  28. Centers for Disease Control and Prevention. Questions & Answers: seasonal influenza associated hospitalizations in the United States. http://www.cdc.gov/flu/about/qa/hospital.htm . Accessed August 21, 2013.
  29. World Health Organization Writing Group. Nonpharmaceutical interventions for pandemic influenza, international measures. Emerg Infect Dis. 2006;12:81-87.
  30. Centers for Disease Control and Prevention. Protecting against influenza (flu): advice for caregivers of children less than 6 months old. http://www.cdc.gov/flu/protect/infantcare.htm . Accessed August 21, 2013.
  31. Centers for Disease Control and Prevention. Antiviral agents for the treatment and chemoprophylaxis of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. January 21, 2011;60(RR01):1-26.
  32. Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians (current for the 2012-2013 influenza season). http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm . Accessed August 21, 2013.
  33. American Academy of Pediatrics. Policy Statement—Recommendations for Prevention and Control of Influenza in Children, 2012-2013. Committee on Infectious Diseases. Pediatrics; originally published online September 10, 2012. http://pediatrics.aappublications.org/content/130/4/780.full.html . Accessed September 13, 2013.
  34. Centers for Disease Control and Prevention. Final state-level influenza vaccination coverage estimates for the 2010-11 season—United States, National Immunization Survey and Behavioral Risk Factor Surveillance System, August 2010 through May 2011. http://www.cdc.gov/flu/professionals/vaccination/coverage_1011estimates.htm . Accessed September 12, 2013.
  35. RAND Health. Seasonal flu vaccination: why don’t more Americans get it? http://www.rand.org/pubs/research_briefs/RB9572.html. Accessed August 21, 2013.
  36. US Census Bureau. USPOP Clock Projection. 2011. http://www.census.gov/population/www/popclockus.html . Accessed August 21, 2013.
  37. Fiore AE, Fry A, Shay D, Gubareva L, Bresse JS, Uyeki TM; Centers for Disease Control and Prevention. Antiviral agents for the treatment and chemoprophylaxis of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(RR01):1-24. http://www.cdc.gov/h1n1flu/recommendations.htm . Accessed August 21, 2013.
  38. Centers for Disease Control and Prevention. CDC recommendations for influenza antiviral medications remain unchanged. http://www.cdc.gov/media/haveyouheard/stories/influenza_antiviral.html . Accessed August 21, 2013.
  39. Centers for Disease Control and Prevention. Symptom Relief.
    http://www.cdc.gov/getsmart/antibiotic-use/symptom-relief.html . Accessed August 21, 2013.
  40. US Food and Drug Administration. Vaccines: Approved Products, Flumist Quadrivalent.
    http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm293952.htm . Accessed September 12, 2013.
  41. FluMist Quadrivalent: Important Safety and Eligibility Information.
    https://www.flumistquadrivalent.com/consumer/what_is_flumist.html#isiAnchor . Accessed August 1, 2013.
  42. Centers for Disease Control and Prevention. Influenza Antiviral Medications: Summary for Clinicians.
    http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm . Accessed September 12, 2013.
SAVE $10 on a prescription of Tamiflu

Sign Up for Flu Alerts

Stay ahead of the flu.

Flu Alert
example

See larger ›

Flu Alert example

Indications

Tamiflu is a prescription medicine used to treat the flu (influenza) in people 2 weeks of age and older who have had flu symptoms for no more than 2 days. Tamiflu can also reduce the chance of getting the flu in people 1 year and older.

Tamiflu does not prevent bacterial infections that may happen with the flu.

Tamiflu is not a substitute for an annual flu vaccination.

Do not take Tamiflu if you are allergic to oseltamivir phosphate or any of the ingredients in Tamiflu.

Important Safety Information

  • If you have an allergic reaction or a severe rash with Tamiflu, stop taking it, and contact your doctor right away. This may be very serious.
  • People with the flu, particularly children and adolescents, may be at an increased risk of seizure, confusion, or abnormal behavior early during their illness.
  • Let your doctor know if you are pregnant, nursing, have heart problems, breathing problems, a weakened immune system (immunocompromised), kidney problems or other medical conditions as Tamiflu may not be right for you.
  • Also tell your doctor about any medications you are taking or if you've received a nasal-spray flu vaccine in the past two weeks.
  • The most common side effects are mild to moderate nausea and vomiting, diarrhea and stomach pain.

Please see the Tamiflu full Prescription Information for complete important safety information.

You are encouraged to report side effects to Genentech by calling 1-888-835-2555 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.